Yamada Daisuke, Kawai Taketo, Sato Yusuke, Yamada Yuta, Akiyama Yoshiyuki, Miyakawa Jimpei, Takahashi Sayuri, Kume Haruki
Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Urology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
GHM Open. 2021 Aug 31;1(1):28-30. doi: 10.35772/ghmo.2021.01024.
Self-isolation to prevent the spread of the novel coronavirus SARS-CoV-2 began in April 2020. As a result, the number of prostate needle biopsies taken at our hospital for suspicion of prostate cancer decreased by 30.5%, from 403 in 2019 to 280 in 2020. The number of diagnoses of prostate cancer decreased by 35.4% from 189 to 122. High-risk and intermediate-risk prostate cancers were 36.5% and 49.7%, respectively, in 2019. Assuming that this situation in our hospital reflects events nationwide, approximately 32,575 (high-risk; 11,890, intermediate risk; 16,189) patients annually would be suffering delays in diagnosis. Furthermore, > 90% of the decrease are curable cases in their 60s and 70s, with prostate specific antigen levels of 30 ng/mL or less, with stage T2, and N0M0. Widely aware that more than 30,000 prostate cancers might be overlooked nationwide in 2020, we recommend establishing a health checkup system with infection control and undergoing early testing.
为防止新型冠状病毒SARS-CoV-2传播而实施的自我隔离措施于2020年4月开始。结果，我院因怀疑前列腺癌而进行的前列腺穿刺活检数量减少了30.5%，从2019年的403例降至2020年的280例。前列腺癌的诊断数量从189例减少到122例，降幅为35.4%。2019年，高危和中危前列腺癌分别占36.5%和49.7%。假设我院的这种情况反映了全国范围内的情况，那么每年大约有32575名患者（高危；11890例，中危；16189例）会面临诊断延误。此外，减少的病例中超过90%是60多岁和70多岁的可治愈病例，前列腺特异性抗原水平在30 ng/mL或以下，分期为T2、N0M0。鉴于广泛意识到2020年全国可能有超过30000例前列腺癌被漏诊，我们建议建立一个具备感染控制措施的健康检查系统并进行早期检测。
